7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Mandibular Diseases D008336 5 associated lipids
Bone Resorption D001862 7 associated lipids
Foreign-Body Reaction D005549 10 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Bone Neoplasms D001859 5 associated lipids
Fractures, Bone D050723 4 associated lipids
Osteoarthritis D010003 4 associated lipids
Carcinoma D002277 18 associated lipids
Osteonecrosis D010020 5 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Hofbauer LC and Heufelder AE The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. 2001 Arthritis Rheum. pmid:11229454
Leach RJ et al. The genetics of Paget's disease of the bone. 2001 J. Clin. Endocrinol. Metab. pmid:11231972
Hofbauer LC and Heufelder AE [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. 2001 Dtsch. Med. Wochenschr. pmid:11233883
Bolon B et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. 2001 Mol. Ther. pmid:11237676
Sasaki N et al. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. 2001 Nephrol. Dial. Transplant. pmid:11239019
Takeuchi T et al. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. 2001 Biochem. Pharmacol. pmid:11239501
Mori K et al. Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. 2001 Cell. Immunol. pmid:11243701
Michigami T et al. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. 2001 Cancer Res. pmid:11245477
Wada N et al. Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. 2001 J. Periodont. Res. pmid:11246705
Lories RJ and Luyten FP Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. 2001 Clin. Rheumatol. pmid:11254237

Table of Content